📌 En este póster destacamos 5 medicamentos clave que se utilizan con frecuencia en la práctica clínica.

#CancerDePulmon #Inmunoterapia #TerapiaDirigida #Quimioterapia #InnovacionMedica #Pembrolizumab #Osimertinib #Alectinib #Pemetrexed #DengYueMedicinasEnHongKong

This #STTT study shows that #Osimertinib disrupts the MYLK4–CDKAL1 interaction, inhibits pT43-CDKAL1 phosphorylation, and CDKAL1-dependent SALL2 translation to inhibit #CancerStemness & #Chemoresistance in #Rhabdomyosarcoma.

#OpenAccess: doi.org/10.1038/s413...

Osimertinib: Guía Completa sobre Usos, Beneficios y Efectos Secundarios ¿Qué es Osimertinib y para qué se utiliza? Osimertinib es un medicamento utilizado principalmente en el tratamiento del cáncer de pulmón no microcítico (CPNM) que presenta mutaciones específicas en el gen EGFR (receptor del... The post Osimertinib: Guía Completa sobre Usos, Beneficios y Efectos Secundarios first appeared on SoloSalud.net.

Osimertinib: Guía Completa sobre Usos, Beneficios y Efectos Secundarios #Osimertinib #CáncerDePulmón #Salud

A study published in Nature Communications recently explored the efficacy of osimertinib, administered alone versus its combination with savolitinib, a potent MET inhibitor, as a frontline therapeutic strategy.
#Osimertinib #Cancer
Details: doi.org/10.1038/s414...

MUC1-C drives #inflammatory memory in #NSCLC, sustaining resistance to #Osimertinib & MET TKIs via STAT1/IFN; targeting with M1C ADC abrogates resistance, offering hope for refractory EGFR-mutant NSCLCs. @harvardmed.bsky.social

#OpenAccess in #STTT: doi.org/10.1038/s413...

This #STTT study identifies #Cuproptosis induction enhances #Osimertinib efficacy in #LungCancer, showing that targeting copper-dependent cell death pathways effectively overcomes bypass-mediated resistance.

#OpenAccess: doi.org/10.1038/s413...

This #STTT study analyzes genomic signatures at first-line #Osimertinib failure, identifying MET amplification and #TP53 co-alterations while demonstrating high concordance between tissue and plasma NGS diagnostics.

#STTT #OpenAccess: doi.org/10.1038/s413...

Researchers from @harvardmed.bsky.social show that #MUC1-C drives cell memory response to #Osimertinib resistance in #NSCLC via STAT1, establishing MUC1-C as a key target for #ADC therapies in TKI-refractory patients.

#STTT #OpenAccess: doi.org/10.1038/s413...

#Osimertinib disrupts the MYLK4–CDKAL1 interaction suppresses CDKAL1-dependent SALL2 translation, resulting in impaired #CancerStemCell maintenance and enhanced chemosensitivity in #Rhabdomyosarcoma.

#OpenAccess: doi.org/10.1038/s413...

Copper diethyldithiocarbamate-induced #Cuproptosis enhances sensitivity and overcomes #Osimertinib resistance by reducing Akt phosphorylation, making it a promising strategy for osimertinib-resistant #LungCancer patients.

#OpenAccess: doi.org/10.1038/s413...

Antibodies.com | Antibodies, Proteins, and ELISA Kits Antibodies.com supplies high-quality antibodies, proteins, and ELISA kits to life science researchers at cost-effective prices. Discover more, for less.

#Osimertinib was originally developed to overcome resistance to earlier treatment versions, when resistance to it often begins with a small population of #PersisterCells. The study aimed to uncover signaling changes underlying how these cells survive, and to identify new therapeutic targets.

A multicenter study evaluating the genomic profile signature (GPS) of #NSCLC patients at first-line #Osimertinib failure shows high concordance between tissue & plasma GPS, revealing #EGFR, #TP53, & #MET alterations.

#STTT #OpenAccess: doi.org/10.1038/s413...

🚀From Bench to Paper | MUC1-C: Key Target for TKI-Refractory #NSCLC
MUC1-C drives NSCLC #osimertinib resistance via STAT1/IFN signaling and “inflammatory memory”. The M1C ADC effectively targets #MUC1C–dependent resistant cells—offering new hope for refractory NSCLC. #Oncology

Oncogenic MUC1-C/M1C protein confers #Osimertinib resistance in #NSCLC cells by driving an inflammatory memory response via the STAT1 and #Interferon type I/II pathways and is a target for M1C ADC treatment. @harvardmed.bsky.social

#OpenAccess: doi.org/10.1038/s413...

Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level

A Yale study finds the protein #METTL7A triggers early resistance to #osimertinib by reshaping DNA architecture. Targeting METTL7A could help block resistance before it starts. #lungcancer #adenocarcinoma
➡️ yalecancercenter.org/news-article...

Actinium's ATNM-400 Shows Promise Against Lung Cancer, Outperforming Leading EGFR Mutant Therapies Actinium Pharmaceuticals presents groundbreaking data on ATNM-400, showing it outperforms current EGFR mutant therapies in lung cancer, showcasing its potential in future treatments.

Actinium's ATNM-400 Shows Promise Against Lung Cancer, Outperforming Leading EGFR Mutant Therapies #USA #New_York #Actinium #ATNM-400 #Osimertinib

Research Unveils Cardiac Risks Associated with Osimertinib in Lung Cancer Treatment A comprehensive study from Okayama University highlights the increased risk of heart failure hospitalization linked to Osimertinib, especially in older patients.

Research Unveils Cardiac Risks Associated with Osimertinib in Lung Cancer Treatment #Japan #Lung_Cancer #Okayama #Okayama_University #Osimertinib

New study highlights the value of effective 1L therapy for EGFR-mutated non-small cell lung cancer. #HEOR #lungcancer #osimertinib

Actualmente, existen 3 opciones de tratamiento de primera línea para mutaciones EGFR:

- #Osimertinib
- #Osimertinib + #Quimioterapia
- #Amivantamab + #Lazertinib

Si quieres saber más sobre estos tratamientos, únete al evento con la Dra. Ana Velázquez Mañana, MD MSc FASCO (Velazquez Manana)

A Case Report on the Development of Ulcerative #Colitis During #Osimertinib Therapy for Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell #LungCancer
onlinelibrary.wiley.com/doi/10.1002/...

FLAURA2 Trial: Osimertinib + Chemotherapy Enhances Survival FLAURA2 trial results show that osimertinib+chemotherapy significantly improves PFS and OS in patients with EGFR-mutated advanced NSCLC.

AstraZeneca’s Press Release: FLAURA2 trials results- Osimertinib Plus Chemotherapy Improves NSCLC Survival

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AstraZeneca #FLAURA2 #NSCLC #LungCancer #Osimertinib

#Osimertinib shows high efficacy in EGFR-mutant #NSCLC with brain metastases—91.9% CNS response & 35.2 mo OS. Adding radiotherapy didn't boost outcomes but raised toxicity. Real-world data from #Vietnam support deferring radiation in select patients. #LungCancer #Cancer #Oncology #EGFR

A research team from Tianjin Medical University Cancer Institute & Hospital published their findings in Cancer Biology & Medicine, aiming to demystify the heightened immune toxicity triggered by osimertinib-ICI co-treatment.
#Osimertinib #ICIs
Details: doi.org/10.20892/j.issn.2095-3941.2024.0269

AMP just published!
"Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer"

Full paper here:
www.actamedicaportuguesa.com/revista/inde...

#nonsmallcelllungcarcinoma #drugtherapy #ErbBreceptors #lungneoplasms #osimertinib

A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.

#ELCC2025

🚀 The Future of Targeted Therapy in EGFR-Mutant NSCLC 🧬

3rd-gen EGFR TKIs (e.g., #osimertinib) have reshaped care for advanced NSCLC, but resistance remains a hurdle. Key insights from a Nature Reviews Clinical Oncology review 👇

@natureportfolio.nature.com
@natrevclinoncol.bsky.social

#Onco404

The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC - IASLC - OncoDaily The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC - IASLC / cancer, fight against cancer, Global awareness, Global fight

The recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC – IASLC
@narjustflorezmd.bsky.social

oncodaily.com/blog/iaslc23...

#Cancer #FightAgainstCancer #GlobalAwareness #IASLC #LAURAtrial #LungCancerConsidered #NSCLC #OncoDaily #Oncology #Osimertinib

AstraZeneca receives positive recommendations for lung cancer treatments - PharmaTimes NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care

#AstraZeneca #lungcancer #NICE #Imfinzi #durvalumab #Tagrisso #osimertinib #NICEpositiverecommendation #NICErecommendation #NHSEngland #NHSWales #ESSCLC #CASPIANPhaseIIItrial #overallsurvivalbenefits #ThoracicOncology #NSCLC #ADAURAphase3trial
pharmatimes.com/news/astraze...

Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - OncoDaily Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC / Annals of Oncology, cancer, EGFR-mutated NSCLC, Hidehito Horinouchi, NSCLC,

Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - Hidehito Horinouchi
@hhorinouchi.bsky.social

oncodaily.com/insight/hide...

#AnnalsOfOncology #Cancer #EGFRMutated #NSCLC #Health #OncoDaily #Oncology #Osimertinib #Medicine #Telisotuzumab #Vedotin